溃疡性结肠炎先进疗法安全性的比较:基于行政索赔数据的研究
本研究利用OptumLabs行政索赔数据库,纳入2016至2022年间启动先进治疗且治疗前后各随访至少1年的9430例溃疡性结肠炎患者,比较不同先进疗法的安全性。中位随访27个月,经多因素调整后,抗IL药物和JAK抑制剂相较TNF拮抗剂与更低严重感染风险相关,静脉血栓栓塞和主要不良心血管事件发生率很低且各药物间无显著差异。
要点
- 抗IL药物较TNF拮抗剂和抗整合素药物与更低严重感染风险相关。
- JAK抑制剂较TNF拮抗剂与更低严重感染风险相关。
- 静脉血栓栓塞和主要不良心血管事件发生率低,各药物间无显著差异。
核心结论
- 在真实世界UC队列中,抗IL药物和JAK抑制剂与更低严重感染风险相关,可能提供净获益,尤其对既往暴露于TNF拮抗剂的患者。
研究设计与样本
- 回顾性队列研究,使用OptumLabs Data Warehouse行政索赔数据库,纳入2016至2022年启动治疗的UC患者,要求治疗前后各随访至少1年。
- 共纳入9430例UC患者,接受TNF拮抗剂(n=4111)、抗整合素(n=3165)、抗IL(n=1342)、JAK抑制剂(n=701)或S1P受体调节剂(n=111),中位随访27个月。
- 采用多分类倾向评分逆概率加权,倾向评分通过广义提升模型估计,校正疾病特征、医疗利用、合并症、既往及合并用药和死亡竞争风险。
主要发现
- 抗IL药物相较TNF拮抗剂与更低严重感染风险相关(HR 0.66,95%CI 0.51-0.87)。
- 抗IL药物相较抗整合素药物与更低严重感染风险相关(HR 0.75,95%CI 0.57-0.98)。
- JAK抑制剂相较TNF拮抗剂与更低严重感染风险相关(HR 0.66,95%CI 0.46-0.94)。
- 静脉血栓栓塞发生率范围为1.4-2.0/100人年,主要不良心血管事件发生率范围为0.5-1.0/100人年,各药物间无显著差异。
临床怎么用
- 对于UC患者选择先进疗法时,可考虑抗IL药物或JAK抑制剂以降低严重感染风险,尤其适用于既往TNF拮抗剂暴露者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We conducted a retrospective cohort study comparing the safety of advanced therapies in patients with ulcerative colitis (UC). METHODS: Using an administrative claims database (OptumLabs Data Warehouse), we identified patients with UC who initiated treatment with tumor necrosis factor-α (TNF) antagonists, anti-integrin agents, anti-interleukin, Janus kinase inhibitors (JAK), or sphingosine-1 phosphate receptor modulators between 2016 and 2022 and had followed up for at least 1 year before and after treatment initiation. We compared the risk of serious infections, venous thromboembolism, and major adverse cardiovascular events through multinomial propensity score-based inverse probability weighting, with propensity scores estimated through generalized boosted models that accounted for disease characteristics, healthcare utilization, comorbidities, and previous and concomitant medications, and the competing risk of mortality. We calculated cause-specific hazard ratios (HR) and 95% confidence intervals for multiple treatment comparisons. RESULTS: We included 9,430 patients with UC treated with TNF antagonists (n = 4,111), anti-integrins (n = 3,165), anti-ILs (n = 1,342), JAK inhibitors (n = 701), or sphingosine-1 phosphate receptor modulators (n = 111), followed over median 27 months. After adjusting for confounding variables, anti-ILs were associated with a lower risk of serious infections compared with TNF antagonists (HR, 0.66 [95% confidence interval, 0.51-0.87]) and anti-integrins (HR, 0.75 [0.57-0.98]). JAK inhibitors were associated with a lower risk of serious infections compared with TNF antagonists (HR, 0.66 [0.46-0.94]). The incidence of venous thromboembolism (incidence rate, 1.4-2.0 per 100 py) and major adverse cardiovascular event (0.5-1.0 per 100 py) was very low, without any significant differences across agents. DISCUSSION: In a real-world cohort of patients with UC, anti-ILs and JAK inhibitors were associated with a lower risk of serious infections and may offer net benefit, especially in patients with previous TNF antagonist exposure.
引用
- Ahuja D, Dziegielewski C, Yeh KH, et al. Comparative Safety of Advanced Therapies in Patients With Ulcerative Colitis: An Administrative Claims-Based Study. Am J Gastroenterol. 2025. PMID: 41124702. doi:10.14309/ajg.0000000000003806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。